The real pros and cons of Wegovy, weighed honestly

Step 1: understand what Wegovy actually does

Wegovy works by mimicking GLP-1, a gut hormone released after eating. It slows how quickly the stomach empties, helps you feel full sooner, and reduces appetite signals in the brain. The result, for most people who tolerate it well, is that smaller portions feel satisfying and the pull towards snacking quietens. That is the mechanism behind those STEP 1 trial figures — not a blanket suppression of everything you enjoy eating, which is one of the more persistent misconceptions worth letting go.

Treatment starts at 0.25mg and is titrated upward roughly every four weeks, moving through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, and you can read a full breakdown of what each Wegovy dose involves to understand how that progression works in practice. The prescriber sets that pace based on how well you are tolerating each level. You can read a fuller explanation of how the medicine works on the semaglutide overview page, which covers the mechanism in more depth.

One concrete advantage of the titration design: side effects are usually at their worst during the first weeks at each new level, then settle. For many people, tolerance improves significantly by week three or four at any given dose. That pattern matters when you are weighing up whether early discomfort is likely to persist.

Step 2: take the benefits seriously, but read them in context

The evidence base for Wegovy is substantial. The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight alongside a weight-related condition and found an average 14.9% reduction in body weight over 68 weeks, roughly three times the effect seen with lifestyle changes alone. That is a clinically meaningful difference for conditions like high blood pressure, type 2 diabetes risk and sleep apnoea.

The MHRA's approval of the 7.2mg single-dose pen in April 2026 extended the picture further, with trial data pointing to around 20.7% average loss over 72 weeks at that higher maintenance dose. For people who plateau at 2.4mg or need greater reduction to address their health risks, that is a significant development. If you want to weigh up the pros and cons of Wegovy specifically for weight loss, that page sets out the evidence in that context. The specific benefits of Wegovy are worth reading if that is the angle you want to explore in more detail.

Beyond weight itself, semaglutide holds a UK authorisation for reducing major cardiovascular event risk in eligible adults, a reminder that for some patients the clinical value goes well beyond the number on the scales. A prescriber can tell you whether that dimension is relevant to your own situation.

Step 3: look at the cons without overweighting them

The side-effect profile is real and worth taking seriously. Nausea is the most commonly reported complaint, followed by diarrhoea, constipation, vomiting and indigestion. In the STEP 1 trial, gastrointestinal effects led a meaningful proportion of participants to discontinue treatment, so this is not a trivial consideration. Most people find these effects settle, but some do not, and if you want a clear picture of what the cons of Wegovy actually are, that page goes through them without softening the detail.

On the safety side, the MHRA issued guidance highlighting acute pancreatitis as a known, infrequent but potentially serious risk. Severe, persistent abdominal pain that radiates to the back warrants urgent medical attention. You can report any suspected side effects via the MHRA Yellow Card scheme. There are also specific points around contraception: for those on semaglutide, current NHS guidance does not flag the same pill-absorption concern that applies to tirzepatide, but discussing your contraceptive method with your prescriber is always sensible before starting.

Other practical downsides: Wegovy requires weekly injections, which some people find off-putting (though the oral semaglutide tablet, approved by the MHRA in June 2026, is now an option for those who prefer not to inject). Cost is a factor in private prescribing; you can find an honest breakdown of what treatment pricing involves on the treatment options page. And the medicine is not suitable for everyone: it is not licensed for use in pregnancy, breastfeeding or if you are trying to conceive, and it is not licensed for people under 18.

Step 4: match the evidence to your own circumstances

NICE recommends semaglutide (Wegovy) for weight management within specialist services, for a maximum of two years, for adults with a BMI of 35 or above alongside at least one weight-related condition, with lower BMI thresholds applying for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. The full eligibility criteria from NICE's appraisal TA875 are worth reading if you want to understand where the guidance sits.

For private prescribing, the licensed thresholds are broader: BMI of 30 or above, or 27 or above with a weight-related condition. But eligibility on paper is not the same as clinical suitability for you specifically. A prescriber looks at your full health history, current medicines, any contraindications, and what you are trying to achieve. If you want a balanced view before that conversation, our page covering the pros and cons of Wegovy brings the key considerations together in one place. If you want to explore whether Wegovy might suit your situation, our prescribers carry out a free clinical consultation, reviewed the same day by a GPhC-registered prescriber, not a bot. Our clinical team page gives a sense of who is reviewing your answers.